Guidance Document: Data Requirements for Safety and Effectiveness of Subsequent Entry Inhaled Corticosteroid Products Used for the Treatment of Asthma - Summary
Related guides and help
- Guidance for Industry: Pharmaceutical Quality of Inhalation and Nasal Products (2006)
- Guidance for Industry: Conduct and Analysis of Comparative Bioavailability Studies (2018)
- Guidance for Industry: Comparative Bioavailability Standards: Formulations Used for Systemic Effects (2018)
- Draft Guidance for Industry: Preparation of Comparative Bioavailability Information for Drug Submissions in CTD Format (2004)
Related acts and regulations
From Health Canada
Overview
This guidance is intended to assist sponsors in the collection and analysis of comparative clinical data for Inhaled Corticosteroid (ICS) products used for the treatment of asthma. This guidance applies to products that contain the same medicinal ingredient and have the same conditions of use as the Canadian Reference Product (CRP).
Who this guide is for
- Drug manufacturers
In this guide
- Introduction
- Guidance for implementation
- Enquiries
- Glossary of abbreviations
- References
Download PDF (264 KB, 14 pages)
Details and history
Published: 2018/10/24
Part of topic(s): Guidance on legislation
For assistance
Contact us:
Bureau of Cardiology, Allergy and Neurological Sciences (BCANS)
Therapeutic Products Directorate
Health Products and Food Branch
Health Canada
1600 Scott Street
Holland Cross, Tower B
2nd Floor, Address Locator 3102C1
Ottawa, Ontario
K1A 0K9
E-mail: hc.bcansenquiries.sc@canada.ca
Fax: 613-941-1668
Report a problem or mistake on this page
- Date modified: